Biohaven reports Q1 EPS ($2.32), may not compare to consensus ($1.14)
"In the first quarter of 2018, we continued our strong momentum across our CGRP receptor antagonist and glutamate modulator pipeline programs. The team's stellar performance and progress position us to expect a number of important data announcements and regulatory filings in 2018 and 2019," said Vlad Coric, M.D., CEO of Biohaven. "In our CGRP receptor antagonist platform, we announced positive data from both of our pivotal Phase 3 trials with rimegepant as an acute treatment for migraine, continued our long-term safety study of rimegepant and commenced a clinical trial of our Zydis(R) orally dissolving tablet formulation. We also progressed BHV-3500 toward the clinic for the acute treatment and prevention of migraine. And in our glutamate modulator programs, we continued to progress all three of our drug candidates across multiple indications. Ongoing studies continue with trigriluzole in spinocerebellar ataxia and OCD, while the Alzheimer's disease trial will begin in the second quarter of 2018. We were excited to initiate our expanded access program for sublingual BHV-0223 in ALS and remain on target to submit our NDA in the second half of 2018. Lastly, our oral, low-trapping NMDA antagonist, BHV-5000, is completing nonclinical and Phase 1 work to support later stage development. Our world-class team of clinical and commercial professionals remain dedicated and focused on achieving important milestones over the course of the year."